Rituksimab
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | MabThera, Rituxan |
| Drugs.com | Monografija |
| Način primene | Intravenozno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 0,8 h |
| Identifikatori | |
| CAS broj | 174722-31-7  |
| ATC kod | L01XC02 (WHO) |
| DrugBank | DB00073 |
| ChEMBL | CHEMBL1201576 |
| Hemijski podaci | |
| Formula | C6416H9874N1688O1987S44 |
| Molarna masa | 143859.7 g/mol |
| Fizički podaci | |
| Tačka topljenja | 61 °C (142 °F) |
Rituksimab (Rituxan, MabThera) je himerno monoklonalno antitelo protiv proteina CD20, koji je prvenstveno prisutan na površini imunskih B ćelija. Rituksimab uništava B ćelije i stoga se koristi za lečenje bolesti koji su karakterisane prekomernim brojem B ćelija, preaktivnim B ćelijama, ili disfunkcionim B ćelijama. Time su obuhvaćeni mnogi limfomi, leukemije, odbacivanja transplantata, i autoimunske bolesti.[1][2][3][4][5][6][7][8]
Reference[уреди | уреди извор]
- ^ McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. PMID 9704735
- ^ Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N En
- ^ gl J Med. 2004 Jun 17;350(25):2572-81. PMID 15201414
- ^ Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC: Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005 Apr;78(4):275-80. PMID 15795920
- ^ Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M: The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16. PMID 16705086
- ^ Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003 Jun 26;348(26):2690-1; discussion 2690-1. PMID 12826649
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
| Normativna kontrola: Državne |
|---|
